热烈祝贺！Loncar China BioPharma ETF (CHNA) 登陆纳斯达克！28家中国企业金榜题名！

药时代 2021-12-13

独立生物技术投资人Brad Loncar先生创办的Loncar Investments设立的中国生物制药ETF，Loncar China BioPharma ETF，于2018年8月15日在纳斯达克登陆，代号CHNA。该ETF挑选了28家公司，其中一部分在香港交易所上市，另一部分在美国纳斯达克挂牌。

了解详情，请阅读昨天发布的新闻稿。

药时代将继续密切关注，及时报道。

Loncar China BioPharma ETF (CHNA) Launches on Nasdaq

CHNA offers diversified exposure to leading companies in China’s burgeoning BioPharma industry

August 15, 2018 08:00 AM Eastern Daylight Time

OKLAHOMA CITY--(BUSINESS WIRE)--Today, the Loncar China BioPharma ETF (Nasdaq: CHNA) begins trading on the Nasdaq in the United States. The CHNA ETF seeks to give investors access to China’s rapidly-developing biopharmaceutical industry. It is based on the Loncar China BioPharma Index, an innovative index developed by biotechnology investor Brad Loncar.

Exchange Traded Concepts (ETC) partnered with Loncar Investments on the successful launch of the fund. It invests in 28 companies, 22 of which are listed on the Hong Kong Stock Exchange and six of which are listed on Nasdaq, offering investors distinct, global exposure through the convenience of one security.

“China aims to become a leader in global medicine,” said Brad Loncar, Chief Executive Officer of Loncar Investments. “Regulatory reform and a new rule allowing pre-revenue biotech companies to list on the Hong Kong Stock Exchange may signal a new era for innovative drug development in the region. We think this is an important trend in healthcare, as it has the potential to spur growth and benefit patients worldwide.”

“We are proud to deliver another cutting-edge, biotech-focused product to the market,” said J. Garrett Stevens, CEO of Exchange Traded Concepts. “China’s goal of moving its life sciences industry towards innovation is one of the most exciting themes within biotechnology, and the Loncar China BioPharma ETF gives investors a front row seat to this transformation.”

CHNA comes at an expense ratio of 0.79 percent. It joins the Loncar Cancer Immunotherapy ETF (Nasdaq: CNCR) under the Loncar Funds brand of innovative biotechnology-focused ETFs. For more information about these products, please visit http://www.loncarfunds.com.

About Exchange Traded Concepts: ETC is carving out a niche as a portal to launch new, custom exchange-traded funds efficiently and cost-effectively through a complete turnkey solution. ETC is a private-label ETF advisor with passive and active exemptive relief from the Securities and Exchange Commission (SEC) to launch both domestic and international equity exchange traded funds under the Investment Company Act of 1940. For more information, please go to www.exchangetradedconcepts.com.

About Loncar Investments: Loncar Investments, LLC is committed to making the biotechnology space more approachable to a wider range of investors. It incorporates extensive research into biotech companies and technologies to develop stock market indexes that are focused on precise investment opportunities. Its first two indexes are the Loncar Cancer Immunotherapy Sector Index (LCINDX) and the Loncar China BioPharma Industry Index (LCHINA). The company is principally owned by biotech investor and analyst Brad Loncar.

Opinions expressed are those of ETC and Loncar Investments are subject to change, not guaranteed, and should not be considered investment advice.

点击下方【阅读原文】，可欣赏新闻稿英文原文。谢谢！

推荐阅读

▼